100 related articles for article (PubMed ID: 26514971)
21. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP).
Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ;
MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109
[TBL] [Abstract][Full Text] [Related]
22. Cervical cancer: A comprehensive approach towards extermination.
Bava SV; Thulasidasan AK; Sreekanth CN; Anto RJ
Ann Med; 2016; 48(3):149-61. PubMed ID: 26911282
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of cervical cancer prevention in Central and Eastern Europe and Central Asia.
Berkhof J; Bogaards JA; Demirel E; Diaz M; Sharma M; Kim JJ
Vaccine; 2013 Dec; 31 Suppl 7():H71-9. PubMed ID: 24332299
[TBL] [Abstract][Full Text] [Related]
24. Primary HPV testing versus cytology-based cervical screening in women in Australia vaccinated for HPV and unvaccinated: effectiveness and economic assessment for the National Cervical Screening Program.
Lew JB; Simms KT; Smith MA; Hall M; Kang YJ; Xu XM; Caruana M; Velentzis LS; Bessell T; Saville M; Hammond I; Canfell K
Lancet Public Health; 2017 Feb; 2(2):e96-e107. PubMed ID: 29253402
[TBL] [Abstract][Full Text] [Related]
25. Prophylactic HPV vaccination for women over 18 years of age.
Adams M; Jasani B; Fiander A
Vaccine; 2009 May; 27(25-26):3391-4. PubMed ID: 19200838
[TBL] [Abstract][Full Text] [Related]
26. Human papillomavirus in cervical screening and vaccination.
Crosbie EJ; Kitchener HC
Clin Sci (Lond); 2006 May; 110(5):543-52. PubMed ID: 16597323
[TBL] [Abstract][Full Text] [Related]
27. Trends in incidence and mortality rates of squamous cell carcinoma and adenocarcinoma of cervix--worldwide.
Mathew A; George PS
Asian Pac J Cancer Prev; 2009; 10(4):645-50. PubMed ID: 19827887
[TBL] [Abstract][Full Text] [Related]
28. Reprint of "Cancer of the cervix: A sexually transmitted infection?".
Beral V
Cancer Epidemiol; 2015 Dec; 39(6):1148-51. PubMed ID: 26547359
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus, cervical cancer, and the vaccines.
Tovar JM; Bazaldua OV; Vargas L; Reile E
Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: mathematical modelling analyses.
Barnabas RV; Laukkanen P; Koskela P; Kontula O; Lehtinen M; Garnett GP
PLoS Med; 2006 May; 3(5):e138. PubMed ID: 16573364
[TBL] [Abstract][Full Text] [Related]
31. Long-term clinical impact of introducing a human papillomavirus 16/18 AS04 adjuvant cervical cancer vaccine in Spain.
Gauthier A; Martín-Escudero V; Moore L; Ferko N; de Sanjosé S; Pérez-Escolano I; Catalá-López F; Ferrer E; Bosch FX
Eur J Public Health; 2008 Dec; 18(6):674-80. PubMed ID: 18641420
[TBL] [Abstract][Full Text] [Related]
32. Human papillomavirus vaccination in adolescence.
Russell M; Raheja V; Jaiyesimi R
Perspect Public Health; 2013 Nov; 133(6):320-4. PubMed ID: 24006173
[TBL] [Abstract][Full Text] [Related]
33. Integrating human papillomavirus vaccination in cervical cancer control programmes.
Franco EL; Coutlée F; Ferenczy A
Public Health Genomics; 2009; 12(5-6):352-61. PubMed ID: 19684447
[TBL] [Abstract][Full Text] [Related]
34. Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model.
Gomez JA; Lepetic A; Demarteau N
BMC Public Health; 2014 Nov; 14():1222. PubMed ID: 25424716
[TBL] [Abstract][Full Text] [Related]
35. Using HPV prevalence to predict cervical cancer incidence.
Sharma M; Bruni L; Diaz M; Castellsagué X; de Sanjosé S; Bosch FX; Kim JJ
Int J Cancer; 2013 Apr; 132(8):1895-900. PubMed ID: 22965284
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness analysis of a quadrivalent human papilloma virus vaccine in Mexico.
Reynales-Shigematsu LM; Rodrigues ER; Lazcano-Ponce E
Arch Med Res; 2009 Aug; 40(6):503-13. PubMed ID: 19853192
[TBL] [Abstract][Full Text] [Related]
37. Human Papillomavirus Vaccination and Cervical Cytology Outcomes Among Urban Low-Income Minority Females.
Hofstetter AM; Ompad DC; Stockwell MS; Rosenthal SL; Soren K
JAMA Pediatr; 2016 May; 170(5):445-52. PubMed ID: 26974250
[TBL] [Abstract][Full Text] [Related]
38. HPV and cofactors for invasive cervical cancer in Morocco: a multicentre case-control study.
Berraho M; Amarti-Riffi A; El-Mzibri M; Bezad R; Benjaafar N; Benideer A; Matar N; Qmichou Z; Abda N; Attaleb M; Znati K; El Fatemi H; Bendahhou K; Obtel M; Filali Adib A; Mathoulin-Pelissier S; Nejjari C
BMC Cancer; 2017 Jun; 17(1):435. PubMed ID: 28633667
[TBL] [Abstract][Full Text] [Related]
39. Advances in primary and secondary interventions for cervical cancer: human papillomavirus prophylactic vaccines and testing.
Wheeler CM
Nat Clin Pract Oncol; 2007 Apr; 4(4):224-35. PubMed ID: 17392713
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
